BTCC / BTCC Square / Global Cryptocurrency /
Gilead Sciences Stock Dips as CVS Rejects HIV Prevention Drug

Gilead Sciences Stock Dips as CVS Rejects HIV Prevention Drug

Global Cryptocurrency
Release Time:
2025-08-21 16:38:02
0
BTCCSquare news:

Gilead Sciences shares fell 1% after CVS Health declined to include its new HIV prevention drug, Yeztugo, in commercial plans. The decision, based on clinical, financial, and regulatory factors, marks a setback despite FDA approval in June.

Yeztugo, an injectable treatment for HIV prevention, showed 99.9% efficacy in trials. Gilead had hailed its approval as a historic milestone, but CVS's refusal to cover it under ACA formularies dampens near-term prospects.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users